Screener
ClearPoint Neuro CLPT Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by ClearPoint Neuro in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: ClearPoint Neuro’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 5:00 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-221890
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Allowance for credit losses (recoveries) | (95) | 217 |
| Depreciation and amortization | 86 | 103 |
| Amortization of intangible assets | 504 | — |
| Share-based compensation | 2,218 | 1,908 |
| Payment-in-kind interest | 525 | — |
| Amortization of debt issuance costs and original issue discounts | 42 | — |
| Amortization of lease right of use assets, net of accretion in lease liabilities | 523 | 231 |
| Increase (decrease) in cash resulting from changes in: |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is ClearPoint Neuro's stock-based comp?
- ClearPoint Neuro (CLPT) reported stock-based comp of $2.22M in Q1 2026.
- How has ClearPoint Neuro's stock-based comp changed year-over-year?
- ClearPoint Neuro's stock-based comp increased by 16.2% year-over-year, from $1.91M to $2.22M.
- What is the long-term trend for ClearPoint Neuro's stock-based comp?
- Over 4 years (2021 to 2025), ClearPoint Neuro's stock-based comp has grown at a 40.9% compound annual growth rate (CAGR), from $2.08M to $8.18M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about ClearPoint Neuro's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude